Synthesis of some oxime ether derivatives of 1-(2-naphthyl)-2-(1,2,4- triazol-1-yl)ethanone and their anticonvulsant and antimicrobial activities

Archiv der Pharmazie

Volumn 339, Issue 9, 2006, Pages 513-520

  Karakurt, Arzu ^a   Aytemir, Mutlu D ^a   Stables, James P ^b   Özalp, Meral ^a   Kaynak, F Betül ^a   Özbey, Süheyla ^a   Dalkara, Sevim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

(Arylalkyl)triazoles; Anticonvulsant; Antimicrobial; Oxime ethers; X ray crystallography

Indexed keywords

1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O (2 PROPEN 1 YL)OXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O (2 PROPYL)OXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O (2,4 DICHLOROBENZYL)OXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O (4 CHLOROBENZYL)OXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O (4 NITROBENZYL)OXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O BENZYLOXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O ETHYLOXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O METHYLOXIME; 1 (2 NAPHTHYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANONE O PROPYLOXIME; CEFTAZIDIME; CHLORIDE; ETHER DERIVATIVE; FLUCONAZOLE; HALIDE; HYDROXYLAMINE; KETONE; OXIME DERIVATIVE; PENTETRAZOLE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CHEMICAL REACTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GAIT; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROPRIOCEPTION; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; RAT; SEIZURE; STANDING; STAPHYLOCOCCUS AUREUS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; INJECTIONS, INTRAPERITONEAL; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NAPHTHALENES; OXIMES; RATS; STAPHYLOCOCCUS AUREUS; TRIAZOLES;

EID: 33749562754     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200500248     Document Type: Article

References (29)

1. P. N. Patsalos, Curr. Opin. CPNS Invest. Drugs 1999, 1, 549-562.
2. W. Löscher, D. Schmidt, Epilepsy Res. 1994, 17, 95-134.
3. N. D. P. Cosford, I. A. McDonald, E. J. Schweiger, Annu. Rep. Med. Chem. 1998, 33, 61-70.
4. D. Schmidt in Pharmacology & Therapeutics (Eds.: M. J. Eadie, F. J. E. Vajda), Springer Verlag, Berlin, 1999, Chapter 6.
5. K. A. M. Walker, M. B. Wallach, D. R. Hirschfeld, J. Med. Chem. 1981, 24, 67-74.
6. D. Nardi, A. Tajana, A. Leonardi, R. Pennini, et al., J. Med. Chem. 1981, 24, 727-731.
7. G. Graziani, P. Cazzulini, C. Luca, G. Nava, R. Testa, Arzneim-Forsch./Drug Res. 1983, 33, 1161-1167.
8. D. W. Robertson, J. H. Krushinski, E. E. Beedle, J. D. Leander, et al., J. Med. Chem. 1986, 29, 1577-1586.
9. Ü. Çalis, S. Dalkara, M. Ertan, R. Sunal, Arch. Pharm. (Weinheim) 1988, 321, 841-846.
10. F. Özkanli, S. Dalkara, Ü. Çalis, A. Willke, Arzneim.-Forsch./Drug Res. 1994, 44, 920-924.
11. A. Karakurt, S. Dalkara, M. Özalp, S. Özbey, et al., Eur. J. Med. Chem. 2001, 36, 421-433.
12. G. V. Mixich, K. Thiele, Arzneim.-Forsch./Drug Res. 1979, 29, 1510-1513.
13. G. P. Bodey, Clin. Infect. Dis. 1992, 14, 161-169.
14. T. Immediata, A. R. Day, J. Org. Chem. 1940, 5, 512-527.
15. H. Baji, M. Flammang, T. Kimny, F. Gasquez, et al., Eur. J. Med. Chem. 1995, 30, 617-626.
16. A. Balsamo, M. C. Breschi, G. Chiellini, L. Favero, et al., Eur. J. Med. Chem. 1995, 30, 743-755.
17. S. Emami, A. Shafiee, Heterocycles 2001, 55, 2059-2074.
18. S. Emami, M. Falahati, A. Banifatemi, M. Amanlou, A. Shafiee, Bioorg. Med. Chem. 2004, 12, 3971-3976.
19. A. C. T. North, D. C. Phillips, F. S. Mathews, Acta Cryst. 1968, A24, 351-359.
20. G. M. Sheldrick, SHELXS97. Program for crystal structure refinement. University of Göttingen, Germany 1997.
21. G. M. Sheldrick, SHELXL97. Program for crystal structure refinement. University of Göttingen, Germany 1997.
22. J. K. Johnson, ORTEP II. Report. ORNL-5138 Oak Ridge National Laboratory, Tennessee, USA 1976.
23. E. Kendi, S. Özbey, A. Karakurt, S. Dalkara, Acta Cryst. 1998, C54, 1513-1515.
24. S. Özbey, E. Kendi, A. Karakurt, S. Dalkara, Acta Cryst. 2002, E58, 1269-1271.
25. A. L. Spek, Acta Cryst. 1990, A46, C34.
26. J. P. Stables, H. J. Kupferberg in Molecular and cellular targets for antiepileptic drugs (Eds.: G. Avanzini, P. Tanganelli, M. Avoli), John Libbey & Company Ltd., London 1997, Chapter 16, pp 191-198.
27. H. J. Kupferberg, J. P. Stables in Challenge epilepsy-new anticonvulsant drugs (Eds.: H. Stefan, G. Kramer, B. Mamoli), Blackwell Science Ltd., Boston, 1998, pp 7-29.
28. NCCLS Approved Standard M-27-A, 17 (9) Villanova, PA 1997.
29. NCCLS Approved Standard M7-A, 37 (2), Villanova, PA 1997.